WFRF:(Tandstad T)
Search: WFRF:(Tandstad T) > (2015-2019) > Surveillance vs. ad...
- 5 of 12
- Previous record
- Next record
- To hitlist
Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience
-
- Cohn-Cedermark, G. (author)
- Karolinska Institutet
-
- Ståhl, Olof (author)
- Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
- Tandstad, T. (author)
- (creator_code:org_t)
- 2014-10-01
- 2015
- English.
- In: Andrology. - : Wiley. - 2047-2927 .- 2047-2919. ; 3:1, s. 102-110
- Research review (peer-reviewed)
Abstract
Subject headings
Close
- Although clinical stage I (CS I) testicular cancer is highly curable, the optimal management is controversial. The aims of the Swedish and Norwegian Testicular Cancer Group (SWENOTECA) studies for CS I non-seminoma (NS) and seminoma (S) have been to reduce treatment intensity while maintaining high survival rates, reduce the number of patients needing salvage treatment and implement patient autonomy with regard to adjuvant treatment. During 1998-2010 NS CSI patients with lymphovascular invasion (LVI) of the primary tumor (high risk) were recommended bleomycin, etoposide, cisplatin (BEP)x1. During 2000-2006 S CS I patients had the option to choose surveillance or adjuvant radiotherapy (AR). In 2004, carboplatinx1 (AUC7) was added as a third treatment option. In 2007 a new risk-adapted treatment protocol for S CS I was initiated. Patients with two risk factors (tumor size>4cm, tumor growth in the rete testis) were recommended carboplatinx1 and patients with 0-1 risk factor were recommended surveillance. All patients were provided with oral and written information of possible management options and could choose the other alternative. The relapse rate for NS CS I with BEPx1 was 3.2% for high risk, and 1.6% for low-risk patients. Five-year cause-specific survival was 100%. For S CS I-patients treated before 2007, 14.3% on surveillance relapsed, 3.9% after carboplatin, and 0.8% after AR. Five-year cause-specific survival was 99.9%. For S CS I-patients treated from 2007, a relapse rate <3% was confirmed for patients without risk factors. SWENOTECA considers BEPx1 standard adjuvant treatment in NS CS I high-risk patients. Low-risk patients should have the opportunity to receive BEPx1 following thorough information regarding pros and cons. For S CS I patients without risk factors, adjuvant treatment is not necessary. For patients with risk factors, patient autonomy should be respected.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)
Keyword
- chemotherapy
- clinical stage I
- radiotherapy
- testis cancer
Publication and Content Type
- for (subject category)
- ref (subject category)
- 5 of 12
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Cohn-Cedermark, ...
- Ståhl, Olof
- Tandstad, T.
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Obstetrics Gynae ...
- Articles in the publication
- Andrology
- By the university
- Lund University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
